Skip to main content

Broadly protective anti-viral vaccines

New Content Item
(Image by Angelo Esslinger from Pixabay)

The rapid development of broadly protective anti-viral vaccines has been considered an intervention strategy of primary importance to reduce the spread of viruses – both endemic viruses like influenza, representing a health and economic burden, and new or emerging viruses with pandemic potential. Platforms should be developed to allow producing broadly protective vaccines either directly or after further adaptation to the newly emerged pandemic virus.

Such vaccines should provide protection against several members of the same virus family. Influenza and coronaviruses are not the only pathogens that could be targeted by a universal vaccine approach. There are several other virus families that harbour viruses with pandemic potential, such as HIV, Hepatitis, yellow fever, Ebola, Zika, Dengue, meningitis. Furthermore, universal vaccines against hepatitis C and HIV are still unavailable.

To achieve this goal, there is an urgent need for more research on understanding correlates of broad protection within these virus families, as well as studies exploring vaccine platforms that are designed to induce such protective responses. Research is also ongoing on the opportunities of using existing vaccines against non-related pathogens, like BCG, Polio- or MMR vaccine, to boost innate immunity as a measure to mitigate the outcome of a pandemic virus infection.

This new cross-journal thematic series welcomes research, reviews, methodology articles and short reports exploring recent developments and promising new research avenues for the development of broadly protective anti-viral vaccines, as well as hurdles and limitations. Studies considering aspects of health economics and health services are also in scope in this series, including research funding, international cooperation, and global investment for better pandemic preparedness.

The following journals are accepting submissions to the series:

Virology Journal

One Health Outlook

Manuscripts should be formatted according to the individual journals instructions for authors and submitted via the online submission system. Please indicate clearly in the title page that the manuscript is to be considered for the thematic series ‘Broadly protective anti-viral vaccines’. 

Manuscripts will be peer-reviewed independently by the respective journal. Accepted articles will be published online on a continuous basis.

  1. To stop the spread of the COVID-19 disease, it is crucial to create molecular tools to investigate and diagnose COVID-19. Current efforts focus on developing specific neutralizing monoclonal antibodies (NmAbs)...

    Authors: Seyed Mostafa Mostafavi Zadeh, Ali Ahmad Bayat, Hosein Shahsavarani, Feridoun Karimi-Busheri, Jafar Kiani, Roya Ghods and Zahra Madjd
    Citation: Virology Journal 2024 21:37
  2. Human T-lymphotropic virus 1 (HTLV-1) is associated with the development of several pathologies and chronic infection in humans. The inefficiency of the available treatments and the challenge in developing a prot...

    Authors: D. S. O. Daian e Silva, L. J. Cox, A. S. Rocha, Á. Lopes-Ribeiro, J. P. C. Souza, G. M. Franco, J. L. C. Prado, T. A. Pereira-Santos, M. L. Martins, J. G. A. Coelho-dos-Reis, T. M. Gomes-de-Pinho, F. G. Da Fonseca and E. F. Barbosa-Stancioli
    Citation: Virology Journal 2023 20:304
  3. Influenza A viruses (IAV) are a prevalent respiratory pathogen that can cause seasonal flu and global pandemics, posing a significant global public health threat. Emerging research suggests that IAV infections...

    Authors: LanYing Ma, Lingyun Ji, Tong Wang, Zhe Zhai, PeiWei Su, YaNan Zhang, Yuan Wang, WenXiao Zhao, ZhiChun Wu, HuaYun Yu and HaiJun Zhao
    Citation: Virology Journal 2023 20:260
  4. To investigate the distribution of the incidence and genotypes of human papillomavirus (HPV) among women with cervical cancer (CC) and precancerous cervical lesions in Yueyang City, China, to develop preventio...

    Authors: Min Zeng, Xiaoyun Zhang, LiLi He, Xin Liu, Huawen Liu, Rui Deng, Bo Qiu, Fang Liu, Hang Xiao, Quanlv Li, Wen Li, Chongmei Liu and Yangqing Ge
    Citation: Virology Journal 2023 20:254
  5. The live-attenuated Rift Valley Fever Smithburn (SB) vaccine is one of the oldest products widely used in ruminants for control of RVF infections. Vaccinations with RVF Smithburn result in residual pathogenic ...

    Authors: Matome Selina Matsiela, Leeann Naicker, Thandeka Khoza and Nobalanda Mokoena
    Citation: Virology Journal 2023 20:221
  6. We compared Fakhravac and BBIBP-Corv2 vaccines in a phase III trial.

    Authors: Masoud Solaymani-Dodaran, Pouria Basiri, Milad Moradi, Kimiya Gohari, Ali Sheidaei, Mohammadreza Ahi, Farzad Ghafoori Naeeni, Akram Ansarifar, Zahra Rahimi, Fatemeh Gholami, Ahmad Karimi Rahjerdi, Ramin Hamidi Farahani, Kosar Naderi saffar, Soheil Ghasemi, Ali Shooshtari, Mohsen Honari…
    Citation: Virology Journal 2023 20:154
  7. Mpox (monkeypox) infection cases increased recently in non-Mpox outbreak areas, potentially causing an international threat. The desire to defend against a potential outbreak has led to renewed efforts to deve...

    Authors: Feixia Gao, Cheng He, Min Liu, Ping Yuan, Shihua Tian, Mei Zheng, Linya Zhang, Xu Zhou, Fangjingwei Xu, Jian Luo and Xiuling Li
    Citation: Virology Journal 2023 20:126
  8. Human norovirus (HuNoV) is the leading cause of acute nonbacterial gastroenteritis globally, and its infection is usually self-limited, so most people become past Norovirus (NoV)-infected individuals. It is kn...

    Authors: Yilin Deng, Taojun He, Bin Li, Hanmei Yuan, Fang Zhang, Hui Wu, Jie Ning, Yanping Zhang, Aixia Zhai and Chao Wu
    Citation: Virology Journal 2023 20:115
  9. Vaccine efficacy of conventional influenza vaccines depend on the antigenic similarity between the selected vaccine strain and annual epidemic strain. Since the influenza virus evolves yearly, a vaccine which ...

    Authors: Toshifumi Imagawa, Youta Arasaki, Kenichi Maegawa, Shigeo Sugita and Kuniaki Nerome
    Citation: Virology Journal 2023 20:102
  10. Patients with type 2 diabetes mellitus (T2DM) have been reported to be more susceptible to 2019 novel coronavirus (2019-nCoV) and more likely to develop severe pneumonia. However, the safety and immunological ...

    Authors: Feng Xiang, Boyu Long, Jiaoxia He, Feifei Cheng, Sijing Zhang, Qing Liu, Zhiwei Chen, Hu Li, Min Chen, Mingli Peng, Wenwei Yin, Dongfang Liu and Hong Ren
    Citation: Virology Journal 2023 20:22
  11. In recent years, the traditional cognition of immunological memory being specific to adaptive immunity has been challenged. Innate immunity can mount enhanced responsiveness upon secondary stimulation, and a p...

    Authors: Shiwei Hu, Danhong Xiang, Xinlu Zhang, Lan Zhang, Shengjie Wang, Keyi Jin, Liangshun You and Jian Huang
    Citation: Virology Journal 2022 19:210
  12. Epstein-Barr virus (EBV) is a wide-spread human herpesvirus that is highly associated with infectious mononucleosis and several malignancies. Evaluation of EBV neutralizing antibody titers is important for ser...

    Authors: Ling Zhong, Claude Krummenacher, Wanlin Zhang, Junping Hong, Qisheng Feng, Qinjian Zhao, Yixin Chen, Mu-Sheng Zeng, Yi-Xin Zeng, Miao Xu and Xiao Zhang
    Citation: Virology Journal 2022 19:196
  13. The presentation of Guillain–Barré syndrome (GBS) caused by Japanese encephalitis virus (JEV) is uncommon, although clusters of GBS cases were observed in China in 2018. The underlying mechanism is unclear, pa...

    Authors: Sheng Liu, Jinyong Wang, Jun Yang and Ying Wen
    Citation: Virology Journal 2022 19:139
  14. Vaccination against HCV is an effective measure in reduction of virus-related public health burden and mortality. However, no prophylactic vaccine is available as of yet. DNA-based immunization is a promising ...

    Authors: Ali Shayeghpour, Roya Kianfar, Parastoo Hosseini, Mehdi Ajorloo, Sepehr Aghajanian, Mojtaba Hedayat Yaghoobi, Tayebeh Hashempour and Sayed-Hamidreza Mozhgani
    Citation: Virology Journal 2021 18:248